Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23
Madison Ward, Melinda Gooderham
Abstract
First reported in Wuhan, China, in December 2019, SARS-CoV-2 virus, causing COVID-19, quickly escalated to a global pandemic. This resulted in many clinicians and patients becoming concerned about continuing biologic therapies for immune-mediated inflammatory diseases, such as psoriasis. Given the potential risk of immunosuppression, a number of publications subsequently appeared in the literature, weighing in on whether biologic therapies should be continued in psoriasis patients.1,2 Guidelines were published to help guide clinicians in their decision-making.
Topics & Concepts
MedicineImmunosuppressionPsoriasisAsymptomaticPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)UstekinumabImmunology2019-20 coronavirus outbreakClarithromycinIntensive care medicineDermatologyInternal medicineInfliximabVirologyDiseaseInfectious disease (medical specialty)Tumor necrosis factor alphaHelicobacter pyloriOutbreakPsoriasis: Treatment and PathogenesisCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research